Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 10, Pages 1519
Publisher
MDPI AG
Online
2019-10-11
DOI
10.3390/cancers11101519
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells
- (2019) Katie B. Holmes et al. Oncogenesis
- Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
- (2019) Jeff P. Sharman et al. JOURNAL OF CLINICAL ONCOLOGY
- Chronic lymphocytic leukaemia
- (2018) Michael Hallek et al. LANCET
- Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration
- (2018) Ahmed Y. Ali et al. LEUKEMIA
- Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
- (2017) Iris de Weerdt et al. HAEMATOLOGICA
- Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
- (2017) Andrew D Zelenetz et al. LANCET ONCOLOGY
- Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells
- (2017) Mara Compagno et al. NATURE
- The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
- (2017) Dan A. Landau et al. Nature Communications
- Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells
- (2017) Prexy Modi et al. Oncotarget
- Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
- (2017) Iris de Weerdt et al. HAEMATOLOGICA
- Combenefit: an interactive platform for the analysis and visualization of drug combinations
- (2016) Giovanni Y. Di Veroli et al. BIOINFORMATICS
- BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199
- (2016) K. Bojarczuk et al. BLOOD
- Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma
- (2016) Qingshan Yang et al. CLINICAL CANCER RESEARCH
- Modeling the chronic lymphocytic leukemia microenvironment in vitro
- (2016) Kyle Crassini et al. LEUKEMIA & LYMPHOMA
- Cross-resistance and synergy with bendamustine in chronic lymphocytic leukemia
- (2016) Sara E.F. Kost et al. LEUKEMIA RESEARCH
- A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
- (2015) S. M. O'Brien et al. BLOOD
- High mobility group protein-mediated transcription requires DNA damage marker γ-H2AX
- (2015) Indrabahadur Singh et al. CELL RESEARCH
- Multiple facets of histone variant H2AX: a DNA double-strand-break marker with several biological functions
- (2015) Valentina Turinetto et al. NUCLEIC ACIDS RESEARCH
- CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia
- (2015) Arnau Montraveta et al. Oncotarget
- Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells
- (2014) A. A. El-Mabhouh et al. BLOOD
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia
- (2014) J. R. Brown et al. BLOOD
- PI3Kδ Inhibition Hits a Sensitive Spot in B Cell Malignancies
- (2014) Bart Vanhaesebroeck et al. CANCER CELL
- On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells
- (2014) I. Gehrke et al. CLINICAL CANCER RESEARCH
- Aberrant topoisomerase-1 DNA lesions are pathogenic in neurodegenerative genome instability syndromes
- (2014) Sachin Katyal et al. NATURE NEUROSCIENCE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells
- (2013) Ju-Yoon Yoon et al. APOPTOSIS
- Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis
- (2013) Wei Ding et al. BRITISH JOURNAL OF HAEMATOLOGY
- Use of the γ-H2AX Assay to Investigate DNA Repair Dynamics Following Multiple Radiation Exposures
- (2013) Luca G. Mariotti et al. PLoS One
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
- (2010) S. E. M. Herman et al. BLOOD
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
- (2008) M. Hallek et al. BLOOD
- Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabinein vitro
- (2008) Lilian Amrein et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents
- (2008) L. M. Leoni et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search